Browse > Article
http://dx.doi.org/10.3345/kjp.2010.53.3.380

Respiratory syncytial virus infection cases in congenital heart disease patients  

Shim, Woo Sup (Department of Pediatrics, Sejong Hospital)
Lee, Jae Yeong (Department of Pediatrics, Division of pediatric Cardiology, Seoul St. Mary's Hospital)
Song, Jin Yong (Department of Pediatrics, Sejong Hospital)
Kim, Soo Jin (Department of Pediatrics, Sejong Hospital)
Kim, Sung Hye (Department of Pediatrics, Sejong Hospital)
Jang, So Ick (Department of Pediatrics, Sejong Hospital)
Choi, Eun Yong (Department of Pediatrics, Sejong Hospital)
Publication Information
Clinical and Experimental Pediatrics / v.53, no.3, 2010 , pp. 380-391 More about this Journal
Abstract
Purpose : Respiratory syncytial virus (RSV) is one of the main pathogens causing lower respiratory infections (LRI) in young children, usually of limited severity. However, in congenital heart disease (CHD) patients, one of the high-risk groups for RSV infection, RSV can cause serious illnesses and fatal results. To elucidate the effects of RSV infection in CHD patients, we observed RSV infection cases among CHD patients and non-CHD patients. Methods : On admission of 343 LRI patients over 3 years, 77 cases of RSV infection were detected by the RSV antigen rapid test of nasopharyngeal secretion. We compared RSV infection cases among groups of CHD and non-CHD patients. Results : During the winter season, RSV caused 20-0% of LRI admissions in children. In patients with completely repaired simple left to right (L-R) shunt diseases such as ventricular septal defect, atrial septal defect, and patent ductus arteriosus, RSV infections required short admission days similar to non-CHD patients. In patients with repaired CHD other than simple L-R shunt CHD, for whom some significant hemodynamic problems remained, RSV infection required long admission days with severe clinical course. In children with unrepaired CHD, RSV infection mostly occurred in early infant age, with long admission days. RSV infections within a month after cardiac surgery also required long admission days and severe clinical course. Conclusion : To avoid the tragedic outcome of severe RSV infection in the CHD patients, efforts to find the subgroups of CHD patients at high risk to RSV infection are needed, and effective preventive treatment should be applied.
Keywords
Respiratory syncytial virus (RSV); Bronchiolitis; Pneumonia; Congenital heart defects/disease; Palivizumab;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Noyola DE, Zuviri-Gonzlez A, Castro-Garca JA, Ochoa-Zavala JR. Impact of respiratory syncytial virus on hospital admissions in children younger than 3 years of age. J Infect 2007;54:180-4   DOI   ScienceOn
2 Henrickson KJ, Hall CB. Diagnositic assays for respiratory syncytial virus disease. Pediatr Infect Dis J 2007:26:36-40   DOI   ScienceOn
3 Navarro-Mar JM, Sanbonmatsu-Gmez S, Prez-Ruiz M, De La Rosa-Fraile M. Rapid detection of respiratory viruses by shell vial assay using simultaneous culture of HEp-2, LLCMK2, and MDCK cells in a single vial. J Clin Microbiol 1999;37:2346-7   PUBMED
4 Meberg A, Bruu AL. Respiratory syncytial virus infections in congenital heart defects - hospitalizations and costs. Acta Pediatrica 2006;95:404-6   DOI   ScienceOn
5 Fixler DE. Respirator syncytial virus infection in children with congenital heart disease: a review. Pediatr Cardiol 1996;17:163-8   DOI   PUBMED   ScienceOn
6 Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH. Field evaluation of a respiratory syncytial virs vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol 1969; 89: 449-63   PUBMED   ScienceOn
7 Yount LE, Mahle WT. Economic analysis of Palivizumab in infants with congenital heart disease. Pediatrics 2004;114:1606-11   DOI   ScienceOn
8 Meissner HC. Selected population at increased risk from respiratory syncytial virus infection. Pediatr Infect Dis J 2003;22:40-5   DOI   PUBMED   ScienceOn
9 Vujovic O, Mills J. Preventive and therapeutic strategies for respiratory syncytial virus infection. Curr Opin Pharmacol 2001;1:497-503   DOI   ScienceOn
10 Nguyen DM, Mulder DS, Shennib H. Effect of cadiopulmonary bypass on circulationg lymphocyte function. Ann Thorac Surg 1992; 53: 611-6   DOI   PUBMED   ScienceOn
11 Piedra PA. Clinical experience with respiratory syncytial virus vaccines. Pediatr Infect Dis J 2003; 22:94-9   DOI   ScienceOn
12 Tajima K, Yamamoto F, Kawazoe K, Nakatani I, Sakai H, Abe T, Kawashima Y. Cardiopulmonary bypass and cellular immunity: changes in lymphocyte subsets and natural killer cell activity. Ann Thorac Surg 1993; 55: 625-30   DOI   PUBMED   ScienceOn
13 Openshaw PJ, Culley FJ, Olszewska W. Immunopathogenesis of vaccine-enhanced RSV disease. Vaccine 2002;20:27-31   DOI   ScienceOn
14 Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Steward CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969; 89: 405-21   PUBMED   ScienceOn
15 Committee on Infectious Diseases and Committee on Fetus and Newborn. Prevention of respiratory syncytial virus infections infections: Indications for the use of Palivizumab and update on the use of RSV-IGIV. Pediatrics 1998;102:1211-6   DOI   PUBMED   ScienceOn
16 The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in highrisk infants. Pediatrics 1998; 102: 531-7   DOI   PUBMED   ScienceOn
17 Smyth RI, Openshaw PJ. Bronciolitis. Lancet 2006;368:312-22   DOI   ScienceOn
18 American Academy of Pediatrics, Committee of Infectious Diseases. Respiratory Syncytial Virus. In: Pickering LK, Baker CJ, Long SS, Mcmillan JA, eds. Red Book: 2006 Report of the committee on infectious diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006:560-6
19 Varga SM, Braciale TJ. RSV-induced immunopathology: dynamic interplay between the virus and host immune response. Virology 2002; 295: 203-7   DOI   ScienceOn
20 Committee on Infectious Diseases and Committee on Fetus and Newborn. Respiratory syncytial virus immune globulin intravenous: indication for use. Pediatrics 1997;99:645-50   DOI   PUBMED   ScienceOn
21 Paes BA. Current strategies in the prevention of respiratory syncytial virus disease. Paediatr Respir Rev 2003;4:21-7   DOI   PUBMED   ScienceOn
22 DePalma L, Yu M, McIntosh CL, Swain JA, Davey RJ. Changes in lymphocyte subpopulations as a result of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991;101:240-4   PUBMED
23 Noyola DE, Rodriguez-Moreno G, Sanchez-Alvarado J, Martinez-Wagner R, Ochoa-Zavala JR. Viral etiology of lower respiratory tract infections in hospitalized children in Mexico. Pediatr Infect Dis J 2004:23:118-23   DOI   ScienceOn
24 Simoes EA, Sondheimer HM, Top FH, Meissner HC, Welliver RC, Kramer AA, et al. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. J Pediatr 1998; 133: 492-9   DOI   ScienceOn
25 Meissner HC, Long SS. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Technical report. Pediatrics 2003; 112: 1447-52   DOI   PUBMED   ScienceOn
26 Welliver RC. Review of epidemiology and clinical risk factors for severe RSV infection. J Pediatr 2003;143:112-7   DOI   ScienceOn
27 Jafri HS. Role of chemokines in RSV disease. Pediatr Infect Dis J 2002; 21: 454-6   DOI   PUBMED   ScienceOn
28 Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Policy statement. Pediatrics 2003;112:1442-6   DOI   PUBMED   ScienceOn
29 Feltes TF, Cabalka AK, Messner HC, Piazza FM, Carlin DA, Top FH, et al. Palivizumab prophylaxis reduces hospitalization due to rispiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143:532-40   DOI   ScienceOn
30 Bowles NE, Ni J, Kearney DL, Pauschinger M, Schultheiss HP, McCarthy R, et al. Detection of viruses in myocardial tissues by polymerase chain reaction. evidence of adenovirus as a common cause of myocarditis in children and adults. J Am Coll Cardiol 2003;42:466-72   DOI   ScienceOn
31 MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris TJ, Manning JA. Respiratory syncytial virus infection in infants with congenital heart disease. N Engl J Med 1982;307:397-400   DOI   PUBMED   ScienceOn